We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From The JAMA Web Sites |

Induction/Maintenance Treatment Regimens for HIV

Julio S. G. Montaner, MD
JAMA. 1999;281(18):1680-1682. doi:10.1001/jama.281.18.1680.
Text Size: A A A
Published online


Journal Scan Archive, October 1998
Posted December 21, 1998

Gulick RM, Mellors JW, Havlir D.  et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Gulick RM, Mellors JW, Havlir D.  et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA.1998;280:35-41.
Montaner JSG, Reiss P, Cooper D.  et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA.1998;279:930-937.
Fischl M, Greenberg S, Clumeck N.  et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naïve subjects.In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 127/12230.
Staszewski S, Morales-Ramirez J, Flanigan T.  et al. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [DMP 266-006].In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 22336.
Renaud M, Ait HM, Katlama C.  et al. Dynamics of CD4+ T cell recovery in a large cohort treated with highly active antiretroviral therapy at advanced stages of HIV disease.In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 41179.
Hammer SM, Squires KE, Hughes MD.  et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med.1997;337:725-733.
Hogg RS, Heath KV, Yip B.  et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA.1998;279:450-454.
Palella Jr FJ, Delaney KM, Moorman AC.  et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Raboud JM, Montaner JSG, Conway B.  et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS.1998;12:1619-1624.
Montaner JSG, Raboud JM, Rae S.for the INCAS and AVANTI Study Groups. Adherence to treatment increases duration of virologic suppression regardless of pVL nadir.In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract LB-10.
Carpenter CCJ, Fischl MA, Hammer SM.  et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society–USA Panel. JAMA.1998;280:78-86.
Carr A, Samaras K, Burton S.  et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Carr A, Samaras K, Chisholm DJ, Cooper DA.Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet.1998;351:1881-1883.
Wong JK, Hezareh M, Gunthard HF.  et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science.1997;278:1291-1295.
Finzi D, Hermankova M, Pierson T.  et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.  et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Montaner JSG, Harris M, Mo T, Harrigan PR.Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS.1998;12:1398-1399.
Montaner JSG, Hogg R, Raboud J, Harrigan R, O′Shaughnessy M.Antiretroviral treatment in 1998. Lancet.1998;352:1919-1922.
Cooper DA, Emery S.Therapeutic strategies for HIV infection: time to think hard. N Engl J Med.1998;339:1319-1321.
Hall DB, Montaner JSG, Reiss P.  et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS.1998;12:F41-F44.
Reijers MH, Weverling GJ, Jurriaans S.  et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet.1998;352:185-190.
Havlir DV, Marschner IC, Hirsch MS.  et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Pialoux G, Raffi F, Brun-Vezinet F.  et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1–infected patients. N Engl J Med.1998;339:1269-1276.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

6 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Overcoming the False Dichotomy of Curative vs Palliative Care for Late-Stage HIV/AIDS: "Let Me Live the Way I Want to Live, Until I Can't"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence to Support the Update